Effect of fabomotizole on brain gene expression in MR rats upon open field test

Cover Page

Cite item

Full Text

Abstract

Selective anxiolytic fabomotisol (Afobazol®) has affinity for the Sigma-1 chaperone receptor site, quinone reductase 2 (NQO2) and MAO-A regulatory sites, and melatonin receptor type 1 (MT1 receptor). The analysis of the effect of fabomotisol on the gene expression profile in the brain of MR (Maudsley Reactive) rats was carried out when modeling emotional stress in the open field test. A change in the expression of 14 genes was found, the results of the functional annotation of which show that the mechanisms of action of fabomotisol may be associated with the regulation of translation of proteins (Rpl5, Rpl15, Ncl, Ybx1), synaptic functions (Cplx2, Dlg4, Syngap1, Add1, Rab8b, Klc1, Chn1) and cellular metabolism (Akr1d1, Bcat1, Pkm).

About the authors

Yu. V. Vakhitova

Institute of Pharmacology of the Russian Academy of Medical Sciences

Author for correspondence.
Email: juvv73@gmail.com
Russian Federation, 8, Baltiyskaya street, Moscow, 125315

U. Sh. Kuzmina

Institute of Biochemistry and Genetics, Subdivizion of the Ufa Federal Research Centre of the Russian Academy of Science

Email: juvv73@gmail.com
Russian Federation, 71, October prospect, Ufa, 450054

M. V. Voronin

Institute of Pharmacology of the Russian Academy of Medical Sciences

Email: juvv73@gmail.com
Russian Federation, 8, Baltiyskaya street, Moscow, 125315

L. F. Zainullina

Institute of Pharmacology of the Russian Academy of Medical Sciences

Email: juvv73@gmail.com
Russian Federation, 8, Baltiyskaya street, Moscow, 125315

S. B. Seredenin

Institute of Pharmacology of the Russian Academy of Medical Sciences

Email: juvv73@gmail.com

Academician of the Russian Academy of Science

Russian Federation, 8, Baltiyskaya street, Moscow, 125315

References

  1. Незнамов Г.Г., Сюняков С.А., Чумаков Д.В. и др. // Психиатрия и психофармакотерапия. 2006. Т. 8. № 4. С. 8-13.
  2. Середенин С.Б., Воронина Т.А., Незнамов Г.Г. и др. // Вест. РАМН. 1998. № 11. С. 3-9.
  3. Середенин С.Б., Воронин М.В. // Экспер. клин. фармакол. 2009. Т. 72. № 1. С. 3-11.
  4. Hayashi T. // Psych. Сlin. Neurosci. 2015. V. 69. № 4. P. 179-191.
  5. Cassagnes L.E., Chhour M., Perio P., et al. // Free Radic. Biol. Med. 2018. V. 120. P. 56-61.
  6. Воронин М.В., Аксенова Л.Н., Бунеева О.А. и др. // Бюл. эксперим. биол. мед. 2009. V. 147. № 7. C. 31-33.
  7. Liu J., Clough S.J., Dubocovich M.L. // Genes, brain, behav. 2017. V. 16. № 5. P. 546-553.
  8. Darnell J.C. // Curr. Opin. Genet. Dev. 2011. V. 21. № 4. P. 465-473.
  9. Chen X., Nelson C.D., Li X., Winters C.A., et al. // J. Neurosci. 2011. V. 31. № 17. P. 6329-6338.
  10. Su T.P., Hayashi T., Maurice T., et al. // Trends Pharmacol. Sci. 2010. V. 31. № 12. P. 557-566.
  11. Середенин С.Б., Антипова Т.А., Воронин М.В. и др. // Бюл. эксперим. биол. мед. 2009. V. 148. № 7. C. 53-55.
  12. Абрамова Е.В., Воронин М.В., Середенин С.Б. // Экспер. клин. фармакол. 2017. Т. 80. № 2. С. 3-7.
  13. Lambert J.J., Cooper M.A., Simmons R.D., et al. // Psychoneuroendocrinol. 2009. V. 34. Suppl. 1. S48-58.
  14. Kalinina T., Shimshirt A., Kudryashov N., et al. // Eur. Neuropsychopharmacol. 2019. V. 29. S.499-S500.
  15. Marriott K.S., Prasad M., Thapliyal V., et al. // J. Pharm. Exp. Ther. 2012. V. 343. № 3. P. 578-586.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Russian academy of sciences

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies